| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49790ed5b8ddc5fa27a1d47732c612df |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G73-0253
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G81-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G81-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G73-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14d4138a2c14d42086faf45166e98729
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05fe8979c51c2a802ed191c52d926c5f |
| publicationDate |
2018-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-108503845-A |
| titleOfInvention |
Amphiphilic graft polymer with catechol ligand and its synthesis method and application |
| abstract |
The invention discloses an amphiphilic graft polymer with a catechol ligand and its synthesis method and application. The invention is based on the amphiphilic graft polymer with a catechol ligand as a carrier. delivery system. Poly(ethylene glycol) was grafted onto poly(cystamine bisacrylamide-ethylenediamine), and then modified with 3,4-dihydroxyphenylacetic acid to synthesize polyethylene glycol-grafted-poly(cystamine bisacrylamide) ‑ethylenediamine)‑3,4‑dihydroxyphenylacetic acid (mPEG‑ g ‑PCD‑DA). Subsequently, doxorubicin was encapsulated to form drug-loaded nanomicelles, and then iron ions were added to form core-crosslinked doxorubicin-loaded nanomicelles (DOX‑CCLMs/SS). The delivery system of the invention can maintain stability in the blood environment, can realize charge reversal and enhance cell endocytosis in the tumor microenvironment, and can realize reduction-sensitive and pH-sensitive drug release in tumor cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110755633-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111116904-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110755633-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110078929-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111110853-A |
| priorityDate |
2018-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |